Clinical trials: Partial Response
BRCA or HRR+ Mutated Ovarian Cancer Patients
To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer
This is a prospective, open-label, single arm, multi-center study to assess the real world clinical effectiveness and safety of olaparib maintenance monotherapy as the capsule formulation (in line with the EU approved prescribing…
- Trial name
- ORZORA (NCT02476968)
- Testing
- Olaparib
- Where
- 58 sites in Bulgaria, Canada and 6 more
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis
The objective of this trial is to compare the efficacy of Certolizumab (CZP) (CDP870) in combination with Methotrexate (MTX) to MTX alone in the treatment of signs and symptoms in patients with active rheumatoid arthritis (RA)…
- Trial name
- NCT00993317
- Testing
- CDP870 200mg, Methotrexate
- Where
- 15 sites in South Korea
- Volunteers
- 127 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Gastroesophageal Reflux
Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)
The purpose of this study is to determine the effect of vonoprazan compared to esomeprazole for preventing heartburn symptoms over a 4-week treatment period in participants who have a partial response to treatment with…
- Trial name
- NCT02743949
- Testing
- Vonoprazan, Esomeprazole
- Where
- 39 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 256 people
- Sponsor
- Takeda
Chronic Obstructive Pulmonary Disease
Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study
The purpose of this study is to determine steady-state efficacy and dose response profile and to assess safety and pharmacokinetic profile of nebulized EP-101(SUN101) after 7-day dosing using an investigational high efficiency…
- Trial name
- NCT01426009
- Testing
- EP-101 via nebulizer (eFlow®) 25 ug, EP-101 via nebulizer (eFlow®) 50 ug, EP-101 via nebulizer (eFlow®) 100 ug
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 140 people
- Sponsor
- Sunovion Respiratory Development Inc.
Hepatitis B
A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)
Chronic hepatitis B virus (HBV) infection is a significant worldwide medical problem. GSK3228836 demonstrated target engagement in CHB participants who were not on treatment and in CHB participants on stable nucleos(t)ide…
- Trial name
- B-Clear (NCT04449029)
- Testing
- GSK3228836, Nucleos(t)ide therapy
- Where
- 121 sites in United States, Argentina and 20 more
- Volunteers
- 457 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate
This 2 part study will investigate the safety, tolerability and efficacy of MabT hera in combination with RoActemra in patients with active rheumatoid arthritis despite a stable dose of methotrexate.
- Trial name
- NCT00845832
- Testing
- rituximab [MabThera/Rituxan], tocilizumab [RoActemra/Actemra]
- Where
- 24 sites in France, Germany and 6 more
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)
The objective of this trial is to investigate the efficacy (American College of Rheumatology 20% : ACR20) superiority of two dose regiments of CDP870 versus placebo in combination with MTX in active RA patients who have an…
- Trial name
- NCT00791999
- Testing
- CDP870 400mg, CDP870 200mg, CDP870 100mg
- Where
- 8 sites in Japan
- Volunteers
- 316 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Gastroesophageal Reflux Disease (GERD)
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.
- Trial name
- NCT00394472
- Testing
- AZD3355
- Where
- 38 sites in Australia, Belgium and 6 more
- Volunteers
- 244 people
- Sponsor
- AstraZeneca
Focal Segmental Glomerulosclerosis
Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis
Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis
- Trial name
- AURONA™ (NCT03598036)
- Testing
- Voclosporin
- Where
- 23 sites in United States, Dominican Republic
- Volunteers
- 5 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Gastroesophageal Reflux Disease
A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience
The purpose of the study is to estimate what effect 4 different doses of AZD3355 will have on the number of reflux episodes, in patients who have GERD and still experience symptoms despite proton pump inhibitor (PPI) treatment.
- Trial name
- NCT01043185
- Testing
- AZD3355
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Newly Diagnosed, Advanced Ovarian Cancer
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.
- Conditions
- Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
- Trial name
- SOLO-1 (NCT01844986)
- Testing
- Olaparib 300mg tablets
- Where
- 177 sites in United States, Australia and 13 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Asthma
A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild Asthmatics
The study will measure the early and late asthamtic response using an allergen challenge. This study will evaluate the safety and patients tolerance to repeat inhaled doses of GW870086X using a number of clinical and biological…
- Trial name
- NCT00857857
- Testing
- GW870086X, FP
- Where
- 4 sites in Germany
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Non-Germline BRCA Mutated Ovarian Cancer
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients
The purpose of the study is to assess the efficacy and safety of single-agent olaparib as a maintenance treatment in patients with relapsed High Grade Serous Ovarian Cancer (including patients with primary peritoneal and/or…
- Trial name
- OPINION (NCT03402841)
- Testing
- Olaparib
- Where
- 91 sites in Austria, Belgium and 17 more
- Volunteers
- 279 people
- Sponsor
- AstraZeneca
Erosive Esophagitis
A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically…
- Trial name
- NCT05055128
- Testing
- X842, X842 Dummy, Lansoprazole
- Where
- 42 sites in United States, Bulgaria and 6 more
- Volunteers
- 248 people
- Sponsor
- Cinclus Pharma Holding AB
Pulmonary Disease, Chronic Obstructive
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to further characterize the dose response of GSK573719 at doses of 15.6 micrograms (mcg) to 125 mcg once daily in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- AC4115321 (NCT01372410)
- Testing
- GSK573719, Tiotropium
- Where
- 13 sites in United States
- Volunteers
- 163 people
- Sponsor
- GlaxoSmithKline
Renal Cell Carcinoma
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Renal cell carcinoma (RCC) accounts for more than 200,000 new cases of cancer and over 100,000 cancer deaths annually in the World (Ferlay, et al., 2004).
- Trial name
- NCT01206764
- Testing
- RAD001
- Where
- 22 sites in Algeria, Egypt and 8 more
- Volunteers
- 143 people
- Sponsor
- Novartis Pharmaceuticals
GERD, Acid Reflux Disease
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).
- Conditions
- GERD, Acid Reflux Disease, Heartburn, Regurgitation
- Trial name
- C27 (NCT00703534)
- Testing
- AZD3355, Gelusil®
- Where
- 84 sites in United States
- Volunteers
- 478 people
- Sponsor
- AstraZeneca
Epithelial Ovarian Cancer, Primary Peritoneal
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
- Trial name
- ATHENA (NCT03522246)
- Testing
- Rucaparib, Nivolumab
- Where
- 238 sites in United States, Australia and 22 more
- Volunteers
- 1,097 people
- Sponsor
- pharmaand GmbH
Ovarian Cancer, Breast Cancer
Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum based Chemotherapy and Metastatic…
- Trial name
- SOLI (NCT04330040)
- Testing
- Olaparib
- Where
- 16 sites in India
- Volunteers
- 202 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Open Label Extension for GLYX13-C-202, NCT01684163
Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.
- Trial name
- NCT02192099
- Testing
- Rapastinel (225 mg/450 mg IV administration)
- Where
- 10 sites in United States
- Volunteers
- 61 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc